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 Introduction and Background
Lung cancer and statistics
Cancer and Nanotechnology
 Nano-Medicine Approach






What we have accomplished
What comes next
 Lung cancer is currently the leading cause of cancer-related mortality
due to its poor prognosis and low survival rate.
The American Cancer Society’s estimates for lung cancer in the United
States for 2017 are:
 About 222,500 new cases of lung cancer (116,990 in men and 105,510
in women)





Small-cell lung cancer – a less common type. Occurs in 10-15% of
population.
Non-small-cell lung cancer – the most common type, accounting for
more than 85-90% of cases; can be either squamous cell carcinoma,
adenocarcinoma or large-cell carcinoma.
http://www.cancer.org/cancer/lungcancer/
Types of Lung Cancer
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 Oncogenic mutations in Kirsten rat
sarcoma oncogene homolog (KRAS)
occur in 15%–30% of non-small cell
lung cancer (NSCLC).
 For K-RAS NSCLC, the 5-year
survival rate is less than 50% in phase
I, followed by 73% in phase II and
58% in phase III, which is less than
15% in overall.
 Undruggable!!
What is K-RAS mutant NSCLC?
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Potential anti-tumor drugs: GT and LSL
Ganetespib
Higher surface area to volume ratio
High intracellular uptake.
Reduced toxicity to normal cells.
Targeted specific cells and tissues.
Higher bioavailability.
Why nanoparticle-based drug 
delivery system?
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 Iron oxide nanoparticles (IONP)
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On a final note, we have successfully designed and synthesized
nanoceria as a delivery vehicle carrying unique drug cocktail for the
targeted treatment of NSCLC.
We have achieved significant synergistic effect of the combinational
drugs.
 What Comes Next
Pre-clinical studies
We would like to continue experimenting with drug combinations





Acidic (pH 6) conditions- to increase efficiency.






Tetrazolium dye, MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
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These survival rates include people who die from causes other than cancer.
•The 5-year survival rate for people with stage IA NSCLC is about 49%. For people with stage IB
NSCLC, the 5-year survival rate is about 45%.
•For stage IIA cancer, the 5-year survival rate is about 30%. For stage IIB cancer, the survival rate is
about 31%.
•The 5-year survival rate for stage IIIA NSCLC is about 14%. For stage IIIB cancers the survival rate
is about 5%.
•NSCLC that has spread to other parts of the body is often hard to treat. Metastatic, or stage IV
NSCLC, has a 5-year survival rate of about 1%. Still, there are often many treatment options










Disassembly of the cell organelles.
Changes in phospholipid content present cytoplasmic membrane.
Phosphotidyl Serine try to come out of the cell membrane.
AnnexinV (Natural anti coagulant) Ca2+ dependent 
phospholipid protein.

